Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review
Daniel A Hoffman,1 Charles DeBattista,2 Rob J Valuck,3 Dan V Iosifescu41Neuro-Therapy Clinic, Inc, Denver, CO, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3University of Colorado, SKAGES School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; 4Mood and Anxiety Disorder...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4bd0171a5162435a93c06eb954a42ab5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4bd0171a5162435a93c06eb954a42ab5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4bd0171a5162435a93c06eb954a42ab52021-12-02T06:03:38ZMeasuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review1176-63281178-2021https://doaj.org/article/4bd0171a5162435a93c06eb954a42ab52012-06-01T00:00:00Zhttp://www.dovepress.com/measuring-severe-adverse-events-and-medication-selection-using-a-ldquo-a10192https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Daniel A Hoffman,1 Charles DeBattista,2 Rob J Valuck,3 Dan V Iosifescu41Neuro-Therapy Clinic, Inc, Denver, CO, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3University of Colorado, SKAGES School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; 4Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, NY, USAAbstract: We previously reported on an objective new tool that uses quantitative electroencephalography (QEEG) normative- and referenced-electroencephalography sampling databases (currently called Psychiatric EEG Evaluation Registry [PEER]), which may assist physicians in determining medication selection for optimal efficacy to overcome trial-and-error prescribing. The PEER test compares drug-free QEEG features for individual patients to a database of patients with similar EEG patterns and known outcomes after pharmacological interventions. Based on specific EEG data elements and historical outcomes, the PEER Report may also serve as a marker of future severe adverse events (eg, agitation, hostility, aggressiveness, suicidality, homicidality, mania, hypomania) with specific medications. We used a retrospective chart review to investigate the clinical utility of such a registry in a naturalistic environment.Results: This chart review demonstrated significant improvement on the global assessment scales Clinical Global Impression – Improvement and Quality of Life Enjoyment and Satisfaction – Short Form as well as time to maximum medical improvement and decreased suicidality occurrences. The review also showed that 54.5% of previous medications causing a severe adverse event would have been raised as a caution had the PEER Report been available at the time the drug was prescribed. Finally, due to the significant amount of off-label prescribing of psychotropic medications, additional, objective, evidence-based data aided the prescriber toward better choices.Conclusion: The PEER Report may be useful, particularly in treatment-resistant patients, in helping to guide medication selection. Based on the preliminary data obtained from this chart review, additional studies are warranted to establish the safety and efficacy of adding PEER data when making medication decisions.Keywords: PEER, referenced-EEG, QEEG, adverse events, medication selection, off labelHoffman DADeBattista CValuck RJIosifescu DVDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 277-284 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hoffman DA DeBattista C Valuck RJ Iosifescu DV Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| description |
Daniel A Hoffman,1 Charles DeBattista,2 Rob J Valuck,3 Dan V Iosifescu41Neuro-Therapy Clinic, Inc, Denver, CO, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3University of Colorado, SKAGES School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; 4Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, NY, USAAbstract: We previously reported on an objective new tool that uses quantitative electroencephalography (QEEG) normative- and referenced-electroencephalography sampling databases (currently called Psychiatric EEG Evaluation Registry [PEER]), which may assist physicians in determining medication selection for optimal efficacy to overcome trial-and-error prescribing. The PEER test compares drug-free QEEG features for individual patients to a database of patients with similar EEG patterns and known outcomes after pharmacological interventions. Based on specific EEG data elements and historical outcomes, the PEER Report may also serve as a marker of future severe adverse events (eg, agitation, hostility, aggressiveness, suicidality, homicidality, mania, hypomania) with specific medications. We used a retrospective chart review to investigate the clinical utility of such a registry in a naturalistic environment.Results: This chart review demonstrated significant improvement on the global assessment scales Clinical Global Impression – Improvement and Quality of Life Enjoyment and Satisfaction – Short Form as well as time to maximum medical improvement and decreased suicidality occurrences. The review also showed that 54.5% of previous medications causing a severe adverse event would have been raised as a caution had the PEER Report been available at the time the drug was prescribed. Finally, due to the significant amount of off-label prescribing of psychotropic medications, additional, objective, evidence-based data aided the prescriber toward better choices.Conclusion: The PEER Report may be useful, particularly in treatment-resistant patients, in helping to guide medication selection. Based on the preliminary data obtained from this chart review, additional studies are warranted to establish the safety and efficacy of adding PEER data when making medication decisions.Keywords: PEER, referenced-EEG, QEEG, adverse events, medication selection, off label |
| format |
article |
| author |
Hoffman DA DeBattista C Valuck RJ Iosifescu DV |
| author_facet |
Hoffman DA DeBattista C Valuck RJ Iosifescu DV |
| author_sort |
Hoffman DA |
| title |
Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| title_short |
Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| title_full |
Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| title_fullStr |
Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| title_full_unstemmed |
Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review |
| title_sort |
measuring severe adverse events and medication selection using a “peer report” for nonpsychotic patients: a retrospective chart review |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/4bd0171a5162435a93c06eb954a42ab5 |
| work_keys_str_mv |
AT hoffmanda measuringsevereadverseeventsandmedicationselectionusingaampldquopeerreportamprdquofornonpsychoticpatientsaretrospectivechartreview AT debattistac measuringsevereadverseeventsandmedicationselectionusingaampldquopeerreportamprdquofornonpsychoticpatientsaretrospectivechartreview AT valuckrj measuringsevereadverseeventsandmedicationselectionusingaampldquopeerreportamprdquofornonpsychoticpatientsaretrospectivechartreview AT iosifescudv measuringsevereadverseeventsandmedicationselectionusingaampldquopeerreportamprdquofornonpsychoticpatientsaretrospectivechartreview |
| _version_ |
1718400108658163712 |